PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides

Vancouver, British Columbia–(Newsfile Corp. – November 24, 2021) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled “Peptides and Uses Thereof”, application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer.

Compounds in these Peptides may be suitable for the treatment of cancers in which extracellular matrix metalloprotease (“MMP”) or other proteinases such as urokinase-type plasminogen activator (uPa) are implicated. MMPs are known to exert effects on the extracellular microenvironment, for example, degradation of the extracellular matrix, thereby allowing cancer cell invasion.

Gliomas, which represent 40% to 45% of all intracranial tumours, are characterized by their potent ability to infiltrate surrounding normal brain tissue, making them a challenge to treat. Glioblastoma multiforme (“GBM”) is the most common and fatal form of brain cancer, affecting adults between the ages of 45 and 60 years. Current treatments for GBM include chemotherapy, radiotherapy and surgery, with the survival of most patients being about one year from diagnosis.

The provisional patent application is to protect the peptides comprising D-amino acids identified in the BSV research project. These peptides have the potential, at least in part, to work as an MMP inhibitor.

PreveCeutical’s Chief Executive Officer, Mr. Stephen Van Deventer, commented, “We are very pleased with the BSV Program outcomes. In addition to the provisional patent filed for the lead peptides in December 2020, PreveCeutical has now filed another patent for Peptides comprising D-amino acids. Possible treatments from the peptides identified in this patent will further our plans for cancer treatments, including management of GBM”.

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, matters related to the Company’s current and planned research and development programs, including the Analgesic Program, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, including the Company’s research and development activities, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the Analgesic Program, complexities and delays in connection with research and development activities and the actual results of research and development activities, and the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and product development programs as planned, including the Analgesic Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare and cannabis industries in Canada may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104958